Virtual CME Program
4.00 CME/CE Credit
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025
The nation is currently grappling with two major public health challenges: managing acute and chronic pain in a vast number of Americans and addressing the crisis of prescription opioid abuse. Pri-Med’s P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 curriculum is designed to equip practitioners with the skills and knowledge needed to navigate these issues effectively. This is a comprehensive pain management education focusing on improving pain management skills, risk reduction strategies, identifying opioid dependence, abuse, and misuse and more! Join this all-inclusive educational activity to enhance your clinical practice and improve patient outcomes in the context of today's complex public health landscape. This activity is also designed to help you meet the Drug Enforcement Administration (DEA) CME requirements for the MATE Act.
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.
Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies.
This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
CME/CE Information
4.00 AMA PRA Category 1 Credits™, 4.00 ABIM MOC or 4.00 AANP, including 1.38 AANP Pharm
Release Date: 2/19/2025
Expiration Date: 2/19/2026
Topics
Learning Objectives
- Discuss the definitions and mechanisms of pain
- Identify risk factors and stratification for opioid-related aberrant behavior and opioid use disorder as part of the initial assessment
- Apply individualized recommendations for nonpharmacologic and non-opioid treatment options for patients in pain
- Review general characteristics of opioid analgesics including their intended use and risks
- Differentiate among tolerance, physical dependence, and manifestations of opioid use disorder
- Recognize best practices to reduce the risks associated with prescription of opioid analgesics, including safe storage and disposal
- Anticipate and manage adverse effects of opioid use including signs of opioid overdose and the use of naloxone
- Select approaches to safely initiate opioids for the treatment of acute pain and chronic pain
- Identify strategies for ongoing safe and effective use of opioids in patients with chronic pain, including titration, referral, and discontinuation, when appropriate
- Summarize counseling strategies for caregivers and patients on opioid therapy
- Act appropriately to evaluate, treat, or refer patients with opioid use disorder
Faculty
Charles E. Argoff, MD, FABPM
Vice Chair
Professor of Neurology and Urology
Albany Medical College
Director, Comprehensive Pain Center
Director, Pain Management Fellowship
Albany Medical Center
Albany, New York
Oscar A. de Leon-Casasola, MD
Professor of Anesthesiology and Medicine
Senior Vice-Chair
School of Medicine and Biomedical Sciences
University at Buffalo
Chief, Pain Medicine and Professor of Oncology
Roswell Park Cancer Institute
Buffalo, New York
Katherine E. Galluzzi, DO, CMD, FACOFP
Professor and Chair
Department of Geriatric and Palliative Medicine
Director, Comprehensive Care
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania
Aubrey J. Grant, MD, FACC
Sports Cardiologist, MedStar Health and Georgetown University
Founder and CEO, Equity Commons
Team Cardiologist, Baltimore Ravens, Baltimore Orioles, Washington Capitals
Member, Diversity and Inclusion Committee, American College of Cardiology
Disclosures
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Charles E. Argoff, MD, FABPM: Speaker: AbbVie, Averitas Pharma, Impel, Kowa Pharmaceuticals, Lilly, Lundbeck, Nevro, Scilex, Teva
Researcher: Abbvie; Consultant: Collegium, Nevro, Pain Scripts, Scilex, Tris, Vertex, Xgene Pharma; Stockholder: Pfizer and Trevana; Investigator: Lundbeck and Teva.
Katherine E. Galluzzi, DO, CMD, FACOFP: No relevant financial relationships disclosed.
Oscar A. de Leon-Casasola, MD: Consultant: Merck Pharmaceuticals, Vertex Pharmaceuticals.
Aubrey Grant, MD: No relevant financial relationships disclosed
Moderators and non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
CME/CE Information
AMA PRA Category 1 Credits™
Accreditation Statement
This activity has been planned and implemented inaccordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP
Accreditation Statement
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308.
Designation Statement
This activity is approved for X.XX contact hour of continuing education, which includes X.XX hours of pharmacology.
MOC Credit Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Obtaining Credit
Supporters and Partners
Commercial Supporter
REMS Program Companies
Education Partner
Miller Medical Communications and Equity Commons
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.